Homepage Archive
New Online Resource for CLL Patients and Survivors
View this free webcast program today.
CLL Challenge Grant - $1.5 Million
The Lymphoma Research Foundation has received a $1.5 million CLL Challenge Grant from a generous donor as a result of the partnership with CIG. Contributions will be matched dollar for dollar.
FDA Approves New Treatment for CLL
On October 26, 2009, the U.S. Food and Drug Administration approved ofatumumab (Arzerra) for the treatment of chronic lymphocytic leukemia (CLL).
CLL Research Grants Awarded
Lymphoma Research Foundation announced the second round of funding awarded to David Frank, MD, PhD (Dana-Farber Cancer Institute) and Thomas Kipps, MD, PhD (Moores Cancer Center, University of California, San Diego).
CIG Teleconference - Michael Keating, MB
On April 2, 2009, CIG hosted a teleconference for CLL/SLL Patients featuring Dr. Michael Keating (MD Anderson Cancer Center).
CIG Teleconference - Richard Furman, MD
On August 24, 2009 CIG hosted a teleconference for CLL/SLL patients featuring Dr. Richard Furman (Weill Cornell Medical College, New York-Presbyterian Hospital). Please note: The Q&A from the call is truncated.
CLL/SLL News from LRF's New York Lymphoma Workshop
Read about the information presented at the Lymphoma Research Foundation's New York Lymphoma Workshop for lymphoma patients, survivors and loved ones.
Cephalon Oncology Reimbursement Hotline
This newly created program at Cephalon is designed to help patients and healthcare providers navigate the reimbursement landscape.
Two Lymphoma Drugs Reach the FDA
Ofatumumab and pixantrone submitted to U.S. Food and Drug Administration for Biologics License Application and New Drug Application.
New Investigator Initiated Clinical Study
A phase I/II study of combination dasatinib and lenalidomide in purine analogue-failed chronic lymphomcytic leukemia.
Phase III Study Shows Improvement in Progression-Free Survival in Patients With Relapsed CLL
A Phase III study showed rituximab (RITUXAN) in combination with chemotherapy improved progression-free survival in patients with relapsed chronic lymphocytic leukemia (CLL).
Bendamustine (TREANDA) Approved to Treat CLL
We interviewed Richard R. Furman, MD about the U.S. Food and Drug Administration's March approval of bendamustine to treat chronic lymphocytic leukemia (CLL).
CLL Prognostic Markers: Latest Developments and What They Mean in Patient Outcome
We interviewed Bruce Cheson, MD about the latest developments in CLL prognostic markers and what they mean in patient outcome.
Patient Perspective: Diagnosis, Prognosis, Treatment and State of Mind
One Patient's Point of View by John Balan.
Patient Perspective: A CLL Diagnosis
A CLL diagnosis often leads to many challenges. This article is from the perspective of a long-term survivor and is about all that CLL carries along with it.
FDA Approves New Drug for CLL
The U.S. Food and Drug Administration (FDA) approved bendamustine (Treanda) for the treatment of chronic lymphocytic leukemia.
CLL Highlights and What It Means for Patients
Every year scientists from around the world convene at the American Society of Hematology’s (ASH) annual meeting. The 2007 ASH meeting featured many abstracts on CLL. We interviewed John Byrd, MD to present the highlights on CLL and what it means for patients.
|
